Curious to see your top suppliers emissions?
Book a demo for a pilot project
Book a demo for a pilot project
Edwards Lifesciences Corporation, a leader in the field of heart valve therapies and critical care monitoring, is headquartered in the United States. Founded in 1958, the company has established itself as a pioneer in innovative medical technologies, particularly in the areas of transcatheter heart valves and haemodynamic monitoring systems.
With a strong presence in North America, Europe, and Asia, Edwards Lifesciences focuses on enhancing patient outcomes through its advanced products, such as the SAPIEN heart valve and the FloTrac system. The company is renowned for its commitment to research and development, which has led to numerous industry accolades and a solid market position. Edwards Lifesciences continues to drive advancements in cardiovascular care, making significant contributions to the medical device industry.
+8 vs industry average
Edwards Lifesciences’s score of 47 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Computer Services has below-average carbon intensity
The Computer Services industry has reduced its overall emissions by 11% since 2018
Scope 3 accounts for ••• of total emissions.
Edwards Lifesciences reported Scope 1 emissions of approximately 19,280,000 kg CO2e and Scope 2 emissions of about 9,889,000 kg CO2e in 2025. In 2024, Scope 1 emissions were approximately 24,064,000 kg CO2e, and in 2023, they were around 26,832,000 kg CO2e. For 2020, total Scope 1 emissions were 14,416,000 kg CO2e, Scope 2 emissions were approximately 31,799,000 kg CO2e (market-based), and Scope 3 emissions were about 31,263,000 kg CO2e.
Edwards Lifesciences is committed to reducing its environmental impact. The company aims for carbon neutrality by 2030 and has near-term Science Based Targets initiative (SBTi) commitments. This includes a target to reduce absolute Scope 1 and 2 GHG emissions by 42% by 2030 from a 2021 baseline year. Additionally, the company commits to reducing Scope 3 GHG emissions by 51.6% per USD of value added within the same timeframe. Edwards Lifesciences also plans to transition the majority of its global electricity demand to renewable sources by 2030.
Access structured emission data, company specific factors and auditable source documents
2030
42% reduction in Scope 1
Edwards Lifesciences commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2021 base year. Edwards Lifesciences also com…
2030
42% reduction in Scope 2
Edwards Lifesciences commits to reduce absolute scope 1 and 2 GHG emissions 42% by 2030 from a 2021 base year. Edwards Lifesciences also com…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
No scope 3 category breakdown has been disclosed yet.


Common questions about Edwards Lifesciences’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more